000078261 001__ 78261
000078261 005__ 20231215090947.0
000078261 0247_ $$2doi$$a10.1016/j.ijbiomac.2017.09.103
000078261 0248_ $$2sideral$$a104155
000078261 037__ $$aART-2018-104155
000078261 041__ $$aeng
000078261 100__ $$aEspona-Noguera, A.
000078261 245__ $$aTunable injectable alginate-based hydrogel for cell therapy in Type 1 Diabetes Mellitus
000078261 260__ $$c2018
000078261 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078261 5203_ $$aIslet transplantation has the potential of reestablishing naturally-regulated insulin production in Type 1 diabetic patients. Nevertheless, this procedure is limited due to the low islet survival after transplantation and the lifelong immunosuppression to avoid rejection. Islet embedding within a biocompatible matrix provides mechanical protection and a physical barrier against the immune system thus, increasing islet survival. Alginate is the preferred biomaterial used for embedding insulin-producing cells because of its biocompatibility, low toxicity and ease of gelation. However, alginate gelation is poorly controlled, affecting its physicochemical properties as an injectable biomaterial. Including different concentrations of the phosphate salt Na2HPO4 in alginate hydrogels, we can modulate their gelation time, tuning their physicochemical properties like stiffness and porosity while maintaining an appropriate injectability. Moreover, these hydrogels showed good biocompatibility when embedding a rat insulinoma cell line, especially at low Na2HPO4 concentrations, indicating that these hydrogels have potential as injectable biomaterials for Type 1 Diabetes Mellitus treatment.
000078261 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/DPI2015-65401-C3-1-R$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2016-79092-R$$9info:eu-repo/grantAgreement/ES/ISCII-CIBER/DRUGDIFF$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 645991-DRIVE$$9info:eu-repo/grantAgreement/EC/H2020/645991/EU/Diabetes Reversing Implants with enhanced Viability and long-term Efficacy/DRIVE$$9info:eu-repo/grantAgreement/ES/DGA/T88
000078261 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000078261 590__ $$a4.784$$b2018
000078261 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b52 / 294 = 0.177$$c2018$$dQ1$$eT1
000078261 591__ $$aPOLYMER SCIENCE$$b7 / 85 = 0.082$$c2018$$dQ1$$eT1
000078261 591__ $$aCHEMISTRY, APPLIED$$b9 / 70 = 0.129$$c2018$$dQ1$$eT1
000078261 592__ $$a0.962$$b2018
000078261 593__ $$aBiochemistry$$c2018$$dQ1
000078261 593__ $$aStructural Biology$$c2018$$dQ1
000078261 593__ $$aMolecular Biology$$c2018$$dQ1
000078261 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000078261 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000078261 700__ $$0(orcid)0000-0002-8666-622X$$aCiriza, J.
000078261 700__ $$aCañibano-Hernández, A.
000078261 700__ $$0(orcid)0000-0002-4220-2722$$aFernandez, L.
000078261 700__ $$0(orcid)0000-0003-2410-5678$$aOchoa, I.$$uUniversidad de Zaragoza
000078261 700__ $$aSaenz del Burgo, L.
000078261 700__ $$aPedraz, J.L.
000078261 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000078261 773__ $$g107, PartA (2018), 1261-1269$$pInt. j. biol. macromol.$$tInternational journal of biological macromolecules$$x0141-8130
000078261 8564_ $$s716692$$uhttps://zaguan.unizar.es/record/78261/files/texto_completo.pdf$$yPostprint
000078261 8564_ $$s51662$$uhttps://zaguan.unizar.es/record/78261/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000078261 909CO $$ooai:zaguan.unizar.es:78261$$particulos$$pdriver
000078261 951__ $$a2023-12-15-08:57:20
000078261 980__ $$aARTICLE